In the context of global pharmaceutical companies cutting R&D spending, Kyoto University and about 70 pharmaceutical and IT-related companies have jointly formed research institutes to develop artificial intelligence specifically for the development of new drugs to significantly reduce drug development costs.
In the context of global pharmaceutical companies cutting R&D spending, Kyoto University and about 70 pharmaceutical and IT-related companies have jointly formed research institutes to develop artificial intelligence specifically for the development of new drugs to significantly reduce drug development costs.
According to the statistics of the Japan Pharmaceutical Industry Association, it takes about 10 years for each new drug to be developed, and the cost is as high as 120 billion yen (1 US dollar is equivalent to 110 yen). The newly formed research institute plans to use 20 artificial intelligence to shorten the development cycle of new drugs to three years. The head of the project at Kyoto University said that artificial intelligence can cut the development cycle of new drugs by half or even two-thirds, and the cost is expected to be halved.
The work of artificial intelligence in the development of new drugs includes locking pathogenic proteins, screening for pharmaceutical ingredients that act on proteins, assessing the safety of pharmaceutical ingredients, determining synthesis methods, and developing clinical trial plans to determine efficacy. Screening only for pharmaceutical ingredients, in the past, relying on pharmaceutical companies to investigate a large number of domestic and foreign medical papers and data, time-consuming and labor-intensive, and artificial intelligence can process huge medical literature data faster.
Artificial intelligence has emerged in Japanese medical services, but there is no precedent for the development and application of new drugs. The Japanese government will provide 500 million yen in funding for the project research, hoping that artificial intelligence will help "Made in Japan" to enhance its international competitiveness. In addition to Kyoto University, the University of Tokyo, the Institute of Physical Chemistry, Takeda Pharmaceutical, and Fujitsu will also participate in this project.
Anyang Kayo Amorphous Technology Co.,Ltd is located on the ancient city-Anyang. It was founded in 2011 that specializes in producing the magnetic ring of amorphous nanocrystalline and pays attention to scientific research highly,matches manufacture correspondingly and sets the design,development,production and sale in a body.Our major product is the magnetic ring of amorphous nanocrystalline and current transformer which is applied to the communication, home appliances, electric power, automobile and new energy extensively. We are highly praised by our customers for our good quality,high efficiency,excellent scheme,low cost and perfect sale service.
Our high frequency transformer is mainly used in high frequency switching power supply as high frequency switching power transformer, also used in high frequency inverter power supply and high frequency welding machine as high frequency inverter transformer. According to the working frequency,it can be divided into several grades:10KHZ-50KHZ,50KHZ-100KHZ,100KHZ ~ 500KHZ,500KHZ ~ 1MHz,and more than 1MHz
High Frequency Transformer,Small And Good Transformer,New Developed Transformer,Useful High Frequency Transformer,Hot Sale Transformer
Anyang Kayo Amorphous Technology Co.,Ltd. , https://www.kayoamotech.com